Clinical trial
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the…
NCT02629861 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT02629861 |
|---|---|
| Title | Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab (TEV-48125) vs Placebo for the Preventive Treatment of Episodic Migraine |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | Fremanezumab, Placebo |
| Enrollment | 875 |
| Start date | Mar 23, 2016 |
| Primary completion | Apr 10, 2017 |
| Completion | Apr 10, 2017 |
| First posted | Dec 14, 2015 |
| Last update posted | Nov 9, 2021 |
| Countries | Canada, Czechia, Finland, Israel, Japan, Poland, Russia, Spain, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: